Positive and Negative Regulatory Pathways In Human Lymphoma

人类淋巴瘤的正向和负向调节途径

• 批准号: 7228202
• 负责人: RICHARD J FORD
• 金额: $ 31.86万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-06-25 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7228202
• 关键词: Affect; Antibodies; Apoptosis; Attenuated; Automobile Driving; B-Cell Lymphomas; B-Cell NonHodgkins Lymphoma; B-Lymphocytes; Binding; Binding Proteins; Biological Models; CD40 Ligand; Cell Death; Cell Lineage; Cell Proliferation; Cell Surface Receptors; Cell Survival; Cell membrane; Cell physiology; Cell surface; Cells; Characteristics; Cholesterol; Clinical; Common Neoplasm; Condition; Defect; Development; Diffuse Large-Cell Lymphoma; Disease; Down-Regulation; Ectopic Expression; Exhibits; Feedback; Functional disorder; Future; Gene Expression; Genes; Goals; Growth; Human; Immune system; In Vitro; Incidence; Indium; Inflammatory; Ligand Binding; Link; Lymphoid Cell; Lymphoma; Maintenance; Malignant - descriptor; Malignant Neoplasms; Mediating; Membrane Microdomains; Modeling; Molecular; Molecular Structure; Molecular Target; NF-AT; NF-kappa B; NFKB Signaling Pathway; Nature; Neoplastic Lymphocyte; Non-Hodgkin' s Lymphoma; Nuclear; Oncogenes; Pathway interactions; Pattern; Phenotype; Process; Production; Proteins; Receptor Signaling; Regulation; Regulatory Pathway; Resistance; Role; SKI gene; Signal Pathway; Signal Transduction; Signal Transduction Pathway; Skiing; Sphingolipids; Structure; System; T-Lymphocyte; TNFRSF5 gene; TNFSF5 gene; Therapeutic; Transcription Factor AP-1; Transcriptional Activation; Transforming Growth Factor beta; Tumor Suppressor Proteins; Up-Regulation; base; cell growth; cell type; immune function; in vivo Model; inhibitor/antagonist; lymphoid neoplasm; neoplastic; neoplastic cell; novel; novel therapeutics; receptor; research study; scaffold; therapeutic target; transcription factor; tumor

DESCRIPTION (provided by applicant): Non-Hodgkin's Lymphomas (NHL) are common tumors of the human immune system, primarily of B cell lineage (NHL-B) that have been showing significant unexplained increases in incidence for the last three decades. Unlike normal B-lymphocytes aggressive forms of NHL-B show rapid, dysregulated B lymphocyte growth characteristics, while retaining typical B cell immuno-phenotypes, including expression of characteristic CD40 and SIg. cell surface receptors. Normal B cells, involved in inflammatory, or other immune functions, transduce signals to activate and release, the key transcription factor, NF-kappaB from its cytoplasmic inhibitor; but aggressive NHL-B cells, such as Large B cell Lymphomas (LBCL), show constitutive expression of nuclear NF-kappaB. Our studies have shown that this is accomplished by continually maintaining an assembled, scaffold-like, signaling platform as a concatenate molecular aggregate, called a Signalosome within a lipid raft microdomains, contained within or subjacent to the lymphoma cell membrane. We have developed a hypothetical model of aggressive NHL-B cell pathophysiology that envisions dysregulation of the CD40 mediated signaling pathways as the major mechanism controlling tumor cell growth and other parameters of malignancy. The CD40 Signalosome appears to be initiated through autochthonous production and cognate ligand binding of CD154 (CD40L, gp39) to the CD40 receptor on the lymphoma cell surface. Our studies have indicated that the necessary and sufficient conditions for CD154 expression seem to differ in NHL-B cells from normal activated T lymphocytes, suggesting that the neoplastic lymphocytes show dysregulated gene expression and signaling pathways to mediate autonomous tumor cell growth. Constitutive expression of NF-kappaB in NHL-B can be down-regulated by treatment with specific antibodies or antisense oligos to CD40 or CD154, that disrupt the integrity of the CD40 Signalosomes, resulting in the inhibition of lymphoma cell growth, and the induction of lymphoma cell death in vitro. In this proposal, we will study the molecular characteristics of the CD40 Signalosome, by isolating and sequencing the component proteins of the canonical CD40/NFkB pathway contained within the signalosome, and demonstrate the signaling capabilities of this macromolecular structure. We will also study the signaling pathways controlling gene expression of the CD40 ligand, CD154, that we believe is intimately involved with driving the signalosome pathway, to ascertain the mechanism of its "ectopic" expression, as well as its possible role the aggressive growth pattern and resistance to cell death shown by aggressive NHL-B. In addition to these abnormalities involving lymphoma cell proliferation and cell viability, NHL-B cells also show aberrant expression of the TGF-beta/SMAD-SNO/SKI system, that is responsible for negative growth regulation in normal B lymphocytes (as well as many other functions in most cell types). Our preliminary studies have shown that abnormalities in SNO/SKI gene expression are involved in abrogating the negative regulatory influence of this signaling system in NHL-B that also appears to be linked to the CD40/NFkB system in NHL-B. Our studies will further examine the role of this system in potentiating the biologic, and possibly the clinical aggressiveness of these lymphoid tumors, and explore whether inhibition of the dysregulatory elements in this pathway can have therapeutic potential. We believe that our CD40 Signalosome model will provide an important "roadmap" into the important control mechanisms involved in NHL-B, that can be used for developing new therapeutic approaches for this very important group of human lymphoid neoplasms.

描述（由申请人提供）：非霍奇金淋巴瘤 (NHL) 是人类免疫系统的常见肿瘤，主要是 B 细胞谱系 (NHL-B)，在过去三十年中其发病率一直显示出显着且无法解释的增加。 与正常 B 淋巴细胞不同，NHL-B 的侵袭性形式表现出快速、失调的 B 淋巴细胞生长特征，同时保留典型的 B 细胞免疫表型，包括特征性 CD40 和 SIg 的表达。细胞表面受体。 参与炎症或其他免疫功能的正常 B 细胞会转导信号，从其细胞质抑制剂中激活和释放关键转录因子 NF-κB；但侵袭性 NHL-B 细胞，例如大 B 细胞淋巴瘤 (LBCL)，显示核 NF-κB 的组成型表达。 我们的研究表明，这是通过持续维持一个组装的支架状信号平台作为串联分子聚集体来实现的，该平台称为脂筏微域内的信号体，包含在淋巴瘤细胞膜内或之下。 我们开发了一种侵袭性 NHL-B 细胞病理生理学的假设模型，该模型设想 CD40 介导的信号通路失调是控制肿瘤细胞生长和其他恶性肿瘤参数的主要机制。 CD40 信号体似乎是通过自身产生以及 CD154（CD40L、gp39）与淋巴瘤细胞表面上的 CD40 受体的同源配体结合而启动的。 我们的研究表明，NHL-B 细胞中 CD154 表达的充分必要条件似乎与正常活化的 T 淋巴细胞不同，这表明肿瘤性淋巴细胞表现出失调的基因表达和介导自主肿瘤细胞生长的信号通路。 NHL-B 中 NF-κB 的组成型表达可通过 CD40 或 CD154 的特异性抗体或反义寡核苷酸治疗下调，从而破坏 CD40 信号体的完整性，从而抑制淋巴瘤细胞生长，并在体外诱导淋巴瘤细胞死亡。 在本提案中，我们将通过对信号体中包含的经典 CD40/NFkB 通路的组成蛋白进行分离和测序来研究 CD40 信号体的分子特征，并证明这种大分子结构的信号传导能力。 我们还将研究控制 CD40 配体 CD154 基因表达的信号通路，我们认为 CD154 与驱动信号体通路密切相关，以确定其“异位”表达的机制，以及其在侵袭性 NHL-B 所表现出的侵袭性生长模式和对细胞死亡的抵抗力中的可能作用。 除了涉及淋巴瘤细胞增殖和细胞活力的这些异常之外，NHL-B 细胞还表现出 TGF-β/SMAD-SNO/SKI 系统的异常表达，该系统负责正常 B 淋巴细胞的负生长调节（以及大多数细胞类型的许多其他功能）。 我们的初步研究表明，SNO/SKI 基因表达异常与消除 NHL-B 中该信号系统的负调控影响有关，该信号系统似乎也与 NHL-B 中的 CD40/NFkB 系统有关。 我们的研究将进一步检验该系统在增强这些淋巴肿瘤的生物学和临床侵袭性方面的作用，并探讨抑制该途径中的失调元件是否具有治疗潜力。 我们相信，我们的 CD40 信号体模型将为 NHL-B 所涉及的重要控制机制提供重要的“路线图”，可用于开发针对这一非常重要的人类淋巴肿瘤的新治疗方法。

项目成果

Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.

• DOI: 10.1158/1535-7163.mct-10-0238
• 发表时间: 2010-07
• 期刊: Molecular cancer therapeutics
• 影响因子: 5.7
• 作者: Pham LV;Tamayo AT;Li C;Bornmann W;Priebe W;Ford RJ
• 通讯作者: Ford RJ

Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma.

核 CD40 与 c-Rel 相互作用并增强侵袭性 B 细胞淋巴瘤的增殖。

• DOI: 10.1182/blood-2007-02-073080
• 发表时间: 2007
• 期刊: Blood
• 影响因子: 20.3
• 作者: Zhou,Hai-Jun;Pham,LanV;Tamayo,ArchitoT;Lin-Lee,Yen-Chiu;Fu,Lingchen;Yoshimura,LindaC;Ford,RichardJ
• 通讯作者: Ford,RichardJ

Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.

• DOI: 10.18632/oncotarget.463
• 发表时间: 2012-03
• 期刊: Oncotarget
• 作者: Li C;Thompson MA;Tamayo AT;Zuo Z;Lee J;Vega F;Ford RJ;Pham LV
• 通讯作者: Pham LV